All In Biotech

Free tool

FAERS Monitor: Cleocin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050767 or its brand name (Cleocin, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.

Reports

4,923

Serious

2,973

60% of reports

Hospitalization

1,434

Death reported

353

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity554
  • drug ineffective431
  • rash366
  • diarrhoea320
  • nausea281
  • off label use263
  • pain251
  • fatigue245
  • pruritus207
  • dyspnoea185
  • headache173
  • pyrexia162
  • vomiting157
  • condition aggravated151
  • anxiety149

Reports by year received

View as table
YearReports
200439
200590
200682
200723
200842
200984
2010184
2011110
2012136
2013188
2014185
2015240
2016401
2017280
2018377
2019366
2020283
2021231
2022318
2023334
2024316
2025336
2026276

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,236 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal55412.311.35,756
rashSignal3663.63.3695
pruritusSignal2072.32.0154
anxietySignal1492.21.9102
condition aggravatedSignal1512.11.890
diarrhoeaSignal3202.11.9194
pyrexiaSignal1622.01.781
pain2511.71.582
nausea2811.51.451
vomiting1571.41.220
drug ineffective4311.41.352
dyspnoea1851.41.221
fatigue2451.31.222
off label use2631.31.117
headache1731.21.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.